Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T12:05:52.946Z.
Calculation as of: 2026-10-06T12:05:52.946Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
PEG RATIO
N/A
Braveheart Bio, Inc.
Market Cap
$1.51B
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Braveheart Bio, Inc. (BRVE) | $1.51B | N/A |
| GH Research PLC (GHRS)vs › | $1.52B | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.52B | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.46B | N/A |
| Certara, Inc. (CERT)vs › | $1.57B | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | N/A |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | N/A |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.65B | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.34B | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
